Section Arrow
IGMS.NASDAQ
- IGM Biosciences
Quotes are at least 15-min delayed:2024/10/31 18:53 EDT
Last
 17.085
-0.515 (-2.93%)
Day High 
17.88 
Prev. Close
17.6 
1-M High
20.35 
Volume 
53.69K 
Bid
17.08
Ask
17.14
Day Low
17.035 
Open
17.3 
1-M Low
11.3 
Market Cap 
1.04B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 16.73 
20-SMA 15.74 
50-SMA 14.12 
52-W High 22.5 
52-W Low 4.12 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.57/-3.10
Enterprise Value
1.08B
Balance Sheet
Book Value Per Share
2.06
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
2.13M
Operating Revenue Per Share
0.03
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ELABElevai Labs0.059-0.0339-36.49%-- 
AVTEAerovate Therapeutics2.46+0.27+12.33%-- 
ENSCEnsysce Biosciences0.5754-0.0629-9.85%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.1445-0.0099-6.41%-- 
GLYCGlycoMimetics0.4069-0.0496-10.87%-- 
Quotes are at least 15-min delayed:2024/10/31 18:53 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.